Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | FPR1 | P21462 | 2/20 | 0.43 |
| ▸ | FPR2 | P25090 | 2/20 | 0.43 |
| ▸ | MTTP | P55157 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8243200 | 0.90 | MAPT (0.41) | KIF11MEN1KMT2AEPHX2MAPT | |
| SCHEMBL14494432 | 0.90 | MAPT (0.41) | KIF11MEN1KMT2AEPHX2MAPT | |
| SCHEMBL8212418 | 0.85 | TAAR1 (0.49) | MEN1HPGDKMT2AEPHX2MAPT | |
| SCHEMBL8207992 | 0.81 | KIF11 (0.58) | KIF11MEN1KMT2AEPHX2MAPT | |
| SCHEMBL8215522 | 0.76 | KIF11 (0.52) | KIF11MEN1KMT2AEPHX2MAPT | |
| SCHEMBL14306236 | 0.76 | MAPT (0.69) | MEN1KMT2AEPHX2MAPTCNR1 | |
| SCHEMBL8212684 | 0.76 | ROCK1 (0.38) | MEN1KMT2AMAPT | |
| SCHEMBL6153200 | 0.75 | KMT2A (0.69) | MEN1HPGDTSHRKMT2AEPHX2 | |
| SCHEMBL8208836 | 0.74 | MEN1 (0.52) | MEN1HPGDKMT2AMAPT | |
| SCHEMBL8212593 | 0.74 | SMN1; SMN2 (0.47) | MEN1KMT2AMAPTFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7553864-B2 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553864-B2 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | KIF11 2611/4885MEN1 1218/4885HPGD 711/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | KIF11 3053/4885MEN1 1618/4885HPGD 493/4885 |
| US-20070129378-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, PCSK9, ALPI | KIF11 2932/4885MEN1 1587/4885HPGD 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.